Natixis Rhythm Pharmaceuticals, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Natixis holds 11,187 shares of RYTM stock, worth $655,446. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,187
Previous 43,951
74.55%
Holding current value
$655,446
Previous $1.8 Million
67.52%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding RYTM
# of Institutions
191Shares Held
67.3MCall Options Held
834KPut Options Held
78.6K-
Primecap Management CO Pasadena, CA7.22MShares$423 Million0.28% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$395 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$375 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$356 Million4.44% of portfolio
-
Goldman Sachs Group Inc New York, NY3.88MShares$227 Million0.03% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.26B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...